US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 1.360
- +0.010+0.74%
Close Apr 23 16:00 ET
- 1.420
- +0.060+4.41%
Pre 08:31 ET
25.27MMarket Cap-1638P/E (TTM)
1.374High1.300Low79.11KVolume1.360Open1.350Pre Close104.59KTurnover0.58%Turnover RatioLossP/E (Static)18.58MShares2.33052wk High-13.47P/B18.54MFloat Cap0.40052wk Low--Dividend TTM13.63MShs Float8.180Historical High--Div YieldTTM5.51%Amplitude0.400Historical Low1.322Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
NeuroSense Therapeutics Stock Forum
A bit more
Update
NEWS
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS
Statistically significant slowing of disease progression by 37% in the per-protocol population
Validation of topline data by the American Academy of Neurology
Positive trend towards impacting Neurofilament biomarker level...
Update
PR Newswire· 8 mins ago
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor fo...
NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results.
In a pivotal development for the treatment of Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive results from its Phase 2b PARADIGM trial. The company's lead drug candidate, PrimeC, demonstrated substantial clinical efficacy, marking a significant milest...
Update
6 MINUTES AGO, 8:30 AM EST
VIA PR NEWSWIRE
• PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
• Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
• Further analysis of PARADIGM is on track with neurofilament resu...
Update
ACCESSWIRE 30-Jan-2024 8:32 AM
No comment yet